The Budget Impact of Biosimilar Infliximab (Remsima(®)) for the Treatment of Autoimmune Diseases in Five European Countries

INTRODUCTION: Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a considerable impact on patients’ quality of life and healthcare budgets. Biosimilar infliximab (Remsima(®)) has been authorize...

Descripción completa

Detalles Bibliográficos
Autores principales: Jha, Ashok, Upton, Alex, Dunlop, William C. N., Akehurst, Ron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569679/
https://www.ncbi.nlm.nih.gov/pubmed/26343027
http://dx.doi.org/10.1007/s12325-015-0233-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569679/
https://www.ncbi.nlm.nih.gov/pubmed/26343027
http://dx.doi.org/10.1007/s12325-015-0233-1

Ejemplares similares